FDA clears Plavix for additional heart indication

09/10/2006 | United Press International

The FDA has cleared Bristol-Myers Squibb's and Sanofi's Plavix anti-clotting drug for reducing the risk of fatal heart attack and the risk of a recurrent heart attack, stroke or death in patients with acute STEMI. Patients who have survived a STEMI incident, the most severe form of heart attack, are at higher risk of another heart attack, stroke or death.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL